ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

Montalban X., Gold R., Thompson A. J., Otero-Romero S., Amato M. P., Chandraratna D., ...Daha Fazla

EUROPEAN JOURNAL OF NEUROLOGY, cilt.25, sa.2, ss.215-237, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1111/ene.13536
  • Dergi Adı: EUROPEAN JOURNAL OF NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.215-237
  • Anahtar Kelimeler: demyelinating, disease-modifying, treatment, diseases, GRADE methodology, guideline, multiple sclerosis, neurological disorders, research methods, DISEASE-MODIFYING DRUGS, SUBCUTANEOUS INTERFERON BETA-1A, PLACEBO-CONTROLLED TRIAL, HIGH-YIELD PROCESS, DOUBLE-BLIND, GLATIRAMER ACETATE, PREGNANCY OUTCOMES, CONTROLLED PHASE-3, FOLLOW-UP, INTRAMUSCULAR INTERFERON
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background and purpose: Multiple sclerosis (MS) is a complex disease of the central nervous system. As new drugs are becoming available, knowledge on diagnosis and treatment must continuously evolve. There is therefore a need for a reference tool compiling current data on benefit and safety, to aid professionals in treatment decisions and use of resources across Europe. The European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have joined forces to meet this need. The objective was to develop an evidence- based clinical practice guideline for the pharmacological treatment of people with MS to guide healthcare professionals in the decision- making process.